Change over period: —
NSE · STAR
STAR
-22.4% from the 52-week high · +20.7% above the low
Strides Pharma Science Ltd. engages in the development, manufacture and distribution of Internet Protocol-led generics and bio-pharmaceutical products. The company is headquartered in Bangalore, Karnataka and currently employs 2,850 full-time employees. The company went IPO on 2000-02-03. The firm is focused on the development and manufacture of IP-led niche and pharmaceutical products. The firm operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The firm manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. The company has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). The company is also engaged in manufacturing soft gelatin capsules. The company develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
The short version. STAR reported revenue of ₹1,430 crore for Sep 2026, up 17.1% from a year earlier. Net profit was ₹131 crore (up 2.3% year on year). Return on equity was 17.9% in Mar 2026. Promoter holding was 29.0% in Sep 2026, up 2.18 points over 8 quarters.
1 · The price
How has the stock traded?
STAR trades 22.4% below its 52-week high and 20.7% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹1,430 cr.
Sep 2026 net profit of ₹131 cr.
1.2 pts lower than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1430 | 1265 | 1323 | 1195 | 1221 | 1120 | 1190 | 1154 |
| Net profit | 131 | 157 | 127 | 202 | 128 | 100 | 82 | 88 |
| Net margin % | 9.2 | 12.4 | 9.6 | 16.9 | 10.4 | 8.9 | 6.9 | 7.6 |
| EPS (₹) | 14.19 | 17.02 | 13.77 | 21.93 | 13.84 | 10.81 | 8.92 | 9.54 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4859 | 4565 | 4051 | 3688 | 3070 | 3316 | 2752 | 3012 |
| Net profit | 556 | 3593 | -71 | -203 | -460 | 268 | 36 | 325 |
| Net margin % | 11.4 | 78.7 | -1.7 | -5.5 | -15.0 | 8.1 | 1.3 | 10.8 |
| EPS (₹) | 60.34 | 389.9 | -7.68 | -22.44 | -51.25 | 29.93 | 4.06 | 36.25 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 17.9% in Mar 2026; debt to equity is 0.54.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 17.9 | 140.8 | -3.3 | -9.2 |
| Return on capital % | 21.0 | 21.2 | 12.6 | 7.1 |
| EBITDA margin % | 20.9 | 20.0 | 14.5 | 13.3 |
| Net margin % | 11.1 | 77.7 | -1.7 | -5.4 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 9.8% | 8.3% |
| Profit CAGR | — | 15.7% |
4 · The owners
Who holds it, and are they adding?
Up 2.18 pts over 8 quarters.
Down 0.5 pts over 8 quarters.
Down 1.41 pts over 8 quarters.
+4 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 26.82 | 28.3 | 28.3 | 27.86 | 27.86 | 27.91 | 27.91 | 29.0 | +2.18 |
| FII | 28.48 | 28.32 | 28.02 | 28.51 | 29.52 | 28.68 | 28.39 | 27.98 | -0.5 |
| DII | 16.92 | 13.72 | 13.3 | 12.98 | 13.02 | 14.45 | 15.41 | 15.51 | -1.41 |
| Public | 27.77 | 29.65 | 30.37 | 30.64 | 29.59 | 28.95 | 28.28 | 27.51 | -0.26 |
Mutual fund holdings · Oct 2026
17 schemes hold this stock
13 the month before.
- quant Healthcare Fund8.79% of NAV
- quant Multi Cap Fund2.11% of NAV
- quant Small Cap Fund1.24% of NAV
- Bandhan Small Cap Fund0.97% of NAV
- Motilal Oswal Nifty Microcap 250 Index Fund0.87% of NAV
- Motilal Oswal BSE Healthcare ETF0.44% of NAV
- Bandhan BSE Healthcare Index Fund0.44% of NAV
- ADITYA BIRLA SUN LIFE VALUE FUND0.28% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for STAR are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about STAR
What is the STAR share price?
STAR (STAR) last closed at ₹982.30, up 2.53% on the day. Its 52-week range is ₹793.55 to ₹1,235.10.
What is the market cap of STAR?
STAR has a market capitalisation of about ₹8,831 crore. Its price-to-earnings ratio is 14.3.
How are STAR's latest results?
STAR reported revenue of ₹1,430 crore for Sep 2026, up 17.1% from a year earlier. Net profit was ₹131 crore (up 2.3% year on year). Return on equity was 17.9% in Mar 2026. Promoter holding was 29.0% in Sep 2026, up 2.18 points over 8 quarters.
Who owns STAR?
As of Sep 2026, shareholding was: Promoter 29.0%, FII 27.98%, DII 15.51%, Public 27.51%.
How many mutual funds hold STAR?
17 mutual fund schemes held STAR in October 2026. That compares with 13 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 22 Jul 2025 · Final Dividend - Rs. 4
- 09 Sep 2024 · Final Dividend - Rs. 2.5
- 04 Aug 2023 · Final Dividend - Rs. 1.5
- 05 Aug 2021 · Final Dividend - Rs. 2.5
- 24 Jul 2020 · Final Dividend - Rs. 2
- 22 Aug 2019 · Interim Dividend - Rs. 12
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.